MedPath

Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

Completed
Conditions
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Interventions
Diagnostic Test: Diagnosis of TTR amyloidosis cardiomyopathy
Registration Number
NCT03842163
Lead Sponsor
Pfizer
Brief Summary

The main purpose of this study is to determine the prevalence of ATTR Cardiomyopathy among patients admitted due to Left Ventricular Hypertrophy (LVH) \>15mm of unknown etiology by using a 99mTc-tracer scintigraphy based protocol

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
812
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with LVH of unknown etiologyDiagnosis of TTR amyloidosis cardiomyopathy-
Primary Outcome Measures
NameTimeMethod
Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with cardiac fixation on a radionuclide bone scintigraphy and/or SPECT performed with 99mTc-DPD or 99mTc-PYP or 999mTc-HMDP among participants with LVH from an undiagnosed etiology were reported in this outcome measure. Scintigraphy was defined at each bone site according to the standard grading: Grade 0 = absent cardiac uptake, Grade 1=mild uptake less than bone, Grade 2=moderate uptake equal to bone and Grade 3=high uptake greater than bone.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.

Percentage of Participants With Autonomic Dysfunction: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".

Percentage of Participants With Autonomic Dysfunction: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".

Percentage of Participants With Cardiological Manifestations: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval less than (\<) 80 milliseconds (ms) or greater than (\>) 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.

Percentage of Participants With Cardiological Manifestations: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.

Percentage of Participants With Cardiological Manifestations: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.

Percentage of Participants With Cardiological Manifestations: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.

Percentage of Participants With Laboratory Abnormalities: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.

Percentage of Participants With Laboratory Abnormalities: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Laboratory parameters that were considered as out of range included creatinine \<45 micromole per liter (μmol/L) or greater than 104 μmol/L w; haemoglobin, participants with a value lower than 11.5 grams per deciliter (g/dL) or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 picograms per milliliter (pg/mL); N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.

Percentage of Participants With Laboratory Abnormalities: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.

Number of Participants According to Presence of Neurological Red Flag: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to presence of neurological red flag as 'Yes' or 'No'.

Percentage of Participants With Laboratory Abnormalities: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.

Number of Participants According to Presence of Neurological Red Flag: FAS1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to presence of neurological red flag as 'Yes' or 'No'.

Number of Participants According to Discrepancies Between Scintigraphy Result and Single Photon Emission Computed Tomography (SPECT) Result: FAS1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Grade of scintigraphy evaluated by the investigator and Grade of SPECT: Grade 0 = absent cardiac uptake, Grade 1=mild uptake less than bone, Grade 2=moderate uptake equal to bone and Grade 3=high uptake greater than bone. Only categories with non-zero values were reported.

Cardiological Assessments - Blood Pressure: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

SBP and DBP were evaluated.

Number of Participants According to History of Clinical Parameters at Baseline: FAS 3.1Baseline

Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.

Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.

Cardiological Assessments - Blood Pressure: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were evaluated.

Number of Participants According to History of Clinical Parameters at Baseline: FAS 3.2Baseline

Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.

Cardiological Assessments - Blood Pressure: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

SBP and DBP were evaluated.

Cardiological Assessments - Blood Pressure: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

SBP and DBP were evaluated.

Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.

Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.

Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants who used pacemaker and ICD were reported in this outcome measure.

Number of Participants According to History of Clinical Parameters at Baseline: FAS 2Baseline

Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.

Number of Participants According to History of Clinical Parameters at Baseline: FAS 3Baseline

Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.

Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.

Number of Participants With Atrial Fibrillation Assessment: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.

Number of Participants With Atrial Fibrillation Assessment: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.

Number of Participants With Atrial Fibrillation Assessment: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.

Number of Participants With Atrial Fibrillation Assessment: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.

Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants who used pacemaker and ICD were reported in this outcome measure.

Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants who used pacemaker and ICD were reported in this outcome measure.

Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants who used pacemaker and ICD were reported in this outcome measure.

Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.

Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.

Heart Rate Parameter for Participants Without Paced: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.

Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.

Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.

Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.

Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.

Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.

Heart Rate Parameter for Participants Without Paced: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Sokolow Index: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.

Heart Rate Parameter for Participants Without Paced: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Heart Rate Parameter for Participants Without Paced: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Sokolow Index: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.

Sokolow Index: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.

Left Ventricular Ejection Fraction (LVEF): FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.

Left Ventricular Ejection Fraction (LVEF): FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.

Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.

Sokolow Index: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.

Left Ventricular Ejection Fraction (LVEF): FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.

Left Ventricular Ejection Fraction (LVEF): FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.

Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.

Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.

Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.

LV End Diastolic Diameter: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Left ventricular end-diastolic diameter (LVEDD) reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.

Number of Participants Categorized According to Perseverance of Strain Apical: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to strain apical preserved as 'No' and 'Yes'.

Number of Participants Categorized According to Perseverance of Strain Apical: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to strain apical preserved as 'No' and 'Yes'.

Number of Participants Categorized According to Perseverance of Strain Apical: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to strain apical preserved as 'No' and 'Yes'.

Number of Participants Categorized According to Perseverance of Strain Apical: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to strain apical preserved as 'No' and 'Yes'.

LV End Diastolic Diameter: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.

LV End Diastolic Diameter: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.

Maximum Wall Thickness: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
LV End Diastolic Diameter: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.

Maximum Wall Thickness: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Type of Hypertrophic Pattern: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.

Maximum Wall Thickness: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Type of Hypertrophic Pattern: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.

Maximum Wall Thickness: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
LV Mass Index (LVMI): FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.

Number of Participants According to Type of Hypertrophic Pattern: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.

Number of Participants According to Type of Hypertrophic Pattern: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.

LV Mass Index (LVMI): FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.

LV Mass Index (LVMI): FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.

LV Mass Index (LVMI): FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.

Aortic Valvular Stenosis - Aortic Valve Area: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.

Aortic Valvular Stenosis - Aortic Valve Area: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.

Aortic Valvular Stenosis - Aortic Valve Area: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.

Aortic Valvular Stenosis - Aortic Valve Area: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.

Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.

Percentage of Participants With Transthyretin Amyloid (ATTR): FAS 1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.

Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 2 (FAS 2)During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.

Percentage of Participants With ATTR or With Suspicion of Monoclonal Gammopathy of Undetermined Significance (MGUS) / Light Chain Amyloidosis (AL): FAS 1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.

Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 3 (FAS 3)During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.

Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.

Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.

Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.

Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.

Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants With TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.

Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.

Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.

Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.

Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.

Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a left ventricular (LV) wall thickness greater than or equal to (\>=) 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

Percentage of Participants With Senso-Motor Polyneuropathy: FAS 2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags Electronic Case Report Form (e-CRF) part was considered as participants with a senso-motor polyneuropathy.

Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.

Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.

Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.

Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.

Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.

Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.2During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.

Percentage of Participants With Autonomic Dysfunction: FAS 3During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".

Percentage of Participants With Autonomic Dysfunction: FAS 3.1During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".

Trial Locations

Locations (18)

Centro Hospitalar e Universitario de Coimbra

🇵🇹

Coimbra, Portugal

University Medical Centre Ljubljana - Department of Cardiology

🇸🇮

Ljubljana, Slovenia

CHU de Nantes

🇫🇷

Nantes cedex 1, France

Divisione di Cardiologia

🇮🇹

Bologna, Italy

The Alfred Department of Cardiology

🇦🇺

Melbourne, Australia

CHU de Toulouse

🇫🇷

Toulouse, France

The Prince Charles Hospital

🇦🇺

Chermside, Australia

East Slovak Institute of Cardiovascular Diseases

🇸🇰

Kosice, Slovakia

Centro Hospitalar de Lisboa Central, E.P.E.

🇵🇹

Lisboa, Portugal

Fundeni Clinical Institute

🇷🇴

Bucharest, Romania

Inherited Cardiovascular Diseases - Cardiology Institute

🇷🇴

Bucharest, Romania

Cardiomyopathy Unit, Department of Cardiology

🇪🇸

Majadahonda, Madrid, Spain

Hopital Henri Mondor, Service de Pharmacologie Clinique

🇫🇷

Creteil, France

Medizinische Universität Innsbruck - Universitätsklinik für Innere Medizin III, Kardiologie

🇦🇹

Innsbruck, Austria

Centre Hospitalier Universitaire de Caen

🇫🇷

Caen, Cedex, France

Careggi Hospital

🇮🇹

Florence, Italy

Hospital Universitario A Coruna

🇪🇸

A Coruna, Spain

The Heart Hospital - University College London Hospitals Nhs Foundation Trust

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy